OFEV Efficacy Supported in a New Study

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

PF_ofev efficacy

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015).

The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety of nintedanib (administered at 150 mg, twice a day) in patients with IPF when compared to patients treated with a placebo.


Read more about it:  http://bit.ly/1MhGtCQ